%22%2F%3E%0A%20%20%3Cpath%20d%3D%22M0%20706%20L1536%20432%20L1536%201024%20L0%201024%20Z%22%20fill%3D%22%23f7d56b%22%20opacity%3D%220.18%22%2F%3E%0A%20%20%3Cpath%20d%3D%22M1060%200%20L1536%200%20L1536%201024%20L1250%201024%20Z%22%20fill%3D%22%23d01f2f%22%20opacity%3D%220.38%22%2F%3E%0A%20%20%3Crect%20x%3D%2284%22%20y%3D%2288%22%20width%3D%22210%22%20height%3D%2218%22%20fill%3D%22%23d01f2f%22%2F%3E%0A%20%20%3Ctext%20x%3D%2284%22%20y%3D%22164%22%20fill%3D%22%23ffffff%22%20font-family%3D%22Arial%2C%20Helvetica%2C%20sans-serif%22%20font-size%3D%2264%22%20font-weight%3D%22900%22%3EWORLD%3C%2Ftext%3E%0A%3C%2Fsvg%3E)
world
South China Morning Post World
Mainland China Funds Boost Stakes in Hong Kong Biotech Amid Licensing Deal Surge
Mainland Chinese institutional investors are increasing their holdings in Hong Kong-listed biotechnology firms, attracted by favorable valuations and a rise in cross-border licensing agreements.